Company profile
Domainex Limited
Drug Discovery Services | Enrich Your Medicines Pipeline | Domainex
Enrich your medicines pipeline - Domainex provides a complete range of preclinical drug discovery services tailored to meet all your research needs
Corporate ownership
Updated 06 Jun 2026 16:52
Latest accounts
Financial period: 1 Jan 2024 to 31 Dec 2024
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Termination Director Company With Name Termination Date
OfficersTM01 | Transaction MzQzNjAxODMxOWFkaXF6a2N4
Published 16 Sep 2024 14:21
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Development of a novel fragment screening platform for G protein-Coupled Receptors
1 May 2018 to 30 Apr 2019
"G-protein coupled receptors (GPCRs) are proteins found on the surface of cells: they detect molecules outside the cell and consequently activate internal signalling pathways that mediate cellular responses. GPCRs are one of the most important human drug target classes, and are addressed by 25-30% of marketed drugs. Many GPCRs that are known to have disea...
NSD inhibitors for the treatment of multiple myeloma and other cancers
1 Oct 2015 to 31 Dec 2016
Our aim is to establish the feasibility of finding a new treatment for cancer by targeting a family of three enzymes called the NSDs. Recent academic research has shown that in myeloma and some other types of cancer the NSD family can switch on the production of other proteins that help these cancers grow. This work leads us to believe that a drug which c...
Development of a new treatment for Chronic Obstructive Pulmonary Disease
1 Oct 2014 to 30 Sep 2017
This project aims to deliver an advanced candidate drug for the treatment for Chronic Obstructive Pulmonary Disease (sometimes refered to as emphysema or chronic bronchitis) – a highly debilitating condition that affects more than 200 million people worldwide and leads to over 6 million early deaths every year. The consequent social, economic, and health-...
Proving the feasibility of using SMYD3 inhibitors as therapeutics for treatment of hepatocellular carcinoma and other cancers.
1 Feb 2013 to 31 Jan 2014
Our aim is to establish the feasibility of a new treatment for cancer that works by targeting the enzyme SMYD3. Recent academic research has shown that SMYD3 is not present in normal cells, but in many cancer cells it switches on the production of other proteins that help tumours grow and spread throughout the body. So this work suggests that a drug that ...
Proving the feasibility of IKKe inhibitors as therapeutics for treatment of Chronic Obstructive Pulmonary Disease (COPD)
1 Oct 2012 to 31 Jan 2014
This project aims to establish the feasibility of a new treatment for Chronic Obstructive Pulmonary Disease – a highly debilitating condition that affects more than 200 million people worldwide and leads to over 6 million early deaths every year. The consequent social, economic, and health-care burden is huge. Treatment for COPD usually involves relieving...
A new drug targeting the enzymes TBK1 and IKKe for the treatment of cancer
1 Nov 2011 to 31 Jan 2013
Our aim is to invent a new drug for the treatment of several common cancers through inhibition of the enzymes IKKe and/or TBK1. Recent academic research has shown that blocking these closely-related protein kinases will stop cancer cells growing, and force them to die. Furthermore these enzymes are important in some inflamatory diseases, obesity, and Type...
Novel assays and platforms for testing and controlling regenerative medicine products
1 Aug 2010 to 31 Mar 2011
Awaiting Public Summary